Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

Inflammation and chemerin in colorectal cancer

Authors: Serpil Erdogan, Fatma Meric Yilmaz, Ozan Yazici, Ahmet Yozgat, Sevilay Sezer, Nuriye Ozdemir, Sema Uysal, Tugrul Purnak, Mehmet Ali Sendur, Ersan Ozaslan

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Chemerin is expressed mainly in the adipose tissue. It is an agonist of chemokine-like receptor-1, which is expressed by the immune system cells. Chemerin stimulates the chemotaxis of the immune system cells, and this indicates the function of chemerin and chemokine-like receptor-1 in the immune response. The tumor microenvironment is very important for determining cancer cell growth and spreading. Therefore, we aimed to investigate the association between colorectal cancer, inflammation, and adipokines including chemerin, adiponectin, and vaspin. The study group consisted of patients with colon cancer, whereas the control subjects consisted of patients with benign conditions, diagnosed with colonoscopy. The two groups were compared in terms of the C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, adiponectin, chemerin, and vaspin. A total of 41 (28 men, 13 women) patients with confirmed colon cancer, and 27 (15 men, 12 women) controls without, confirmed by colonoscopy, were enrolled. The median chemerin levels were found significantly higher in the study group than the controls (390 vs. 340 ng/mL, p = 0.032), whereas the mean vaspin and adiponectin levels were not significantly different. The median values for the CRP, fibrinogen, and ESR were significantly higher in the patients with colon cancer, when compared to the control group (6.08 vs. 1.4 mg/L, p < 0.0001; 408 vs. 359 mg/dL, p = 0.002; and 30 vs. 8 mm/h, p < 0.0001, respectively). Our results show that higher levels of circulating chemerin, CRP, fibrinogen, and ESR are associated with an increased risk of developing colorectal cancer.
Literature
1.
2.
go back to reference Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.CrossRefPubMed Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.CrossRefPubMed
3.
go back to reference Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.CrossRefPubMed Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.CrossRefPubMed
4.
go back to reference Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102:10610–5.CrossRefPubMedPubMedCentral Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102:10610–5.CrossRefPubMedPubMedCentral
5.
go back to reference Roh SG, Song SH, Choi KC, et al. Chemerin—a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013–8.CrossRefPubMed Roh SG, Song SH, Choi KC, et al. Chemerin—a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun. 2007;362:1013–8.CrossRefPubMed
6.
go back to reference Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977–85.CrossRefPubMedPubMedCentral Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977–85.CrossRefPubMedPubMedCentral
7.
go back to reference Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem. 2005;280:34661–6.CrossRefPubMed Zabel BA, Allen SJ, Kulig P, et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem. 2005;280:34661–6.CrossRefPubMed
9.
go back to reference Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm. 2014;2014, 292376.CrossRef Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediat Inflamm. 2014;2014, 292376.CrossRef
10.
go back to reference Aggarwal BB. Inflammation, a silent killer in cancer is not so silent! Curr Opin Pharmacol. 2009;9:347–50.CrossRefPubMed Aggarwal BB. Inflammation, a silent killer in cancer is not so silent! Curr Opin Pharmacol. 2009;9:347–50.CrossRefPubMed
11.
12.
go back to reference Gharat L, Rathod GP, Kandalgaonkar S. Quantitative estimation of serum fibrinogen degradation product levels in oral premalignant and malignant lesions. J Int Oral Health. 2013;5:65–72.PubMedPubMedCentral Gharat L, Rathod GP, Kandalgaonkar S. Quantitative estimation of serum fibrinogen degradation product levels in oral premalignant and malignant lesions. J Int Oral Health. 2013;5:65–72.PubMedPubMedCentral
13.
go back to reference Cahlin C, Lonnroth C, Arvidsson A, et al. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 2008;32:909–18.PubMed Cahlin C, Lonnroth C, Arvidsson A, et al. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 2008;32:909–18.PubMed
14.
go back to reference Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.CrossRefPubMed Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047–51.CrossRefPubMed
15.
go back to reference Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRefPubMed Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.CrossRefPubMed
16.
go back to reference Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653–65.PubMedPubMedCentral Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653–65.PubMedPubMedCentral
17.
go back to reference Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology. 2003;50:1910–3.PubMed Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology. 2003;50:1910–3.PubMed
18.
go back to reference Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999;85:2526–31.CrossRefPubMed Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999;85:2526–31.CrossRefPubMed
19.
go back to reference Tempfer C, Zeisler H, Sliutz G, et al. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997;66:27–30.CrossRefPubMed Tempfer C, Zeisler H, Sliutz G, et al. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol. 1997;66:27–30.CrossRefPubMed
20.
go back to reference Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma. Ann Hematol. 2005;84:510–6.CrossRefPubMed Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma. Ann Hematol. 2005;84:510–6.CrossRefPubMed
21.
go back to reference Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res. 2014;34:339–47.PubMed Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma. Anticancer Res. 2014;34:339–47.PubMed
22.
go back to reference van Leeuwen MA, van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol. 1994;8:531–52.CrossRefPubMed van Leeuwen MA, van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol. 1994;8:531–52.CrossRefPubMed
23.
go back to reference Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342–8 e1.CrossRefPubMedPubMedCentral Ananthakrishnan AN, Cheng SC, Cai T, et al. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342–8 e1.CrossRefPubMedPubMedCentral
25.
go back to reference Sung HH, Jeon HG, Jeong BC, et al. Clinical significance of prognosis of the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int. 2014. Sung HH, Jeon HG, Jeong BC, et al. Clinical significance of prognosis of the neutrophil-lymphocyte ratio and erythrocyte sedimentation rate in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int. 2014.
26.
go back to reference Lee DY, Hong SW, Chang YG, et al. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer. 2013;13:111–6.CrossRefPubMedPubMedCentral Lee DY, Hong SW, Chang YG, et al. Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer. 2013;13:111–6.CrossRefPubMedPubMedCentral
27.
go back to reference Wu J, Cai Q, Li H, et al. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis. 2013;34:2799–803.CrossRefPubMedPubMedCentral Wu J, Cai Q, Li H, et al. Circulating C-reactive protein and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis. 2013;34:2799–803.CrossRefPubMedPubMedCentral
28.
go back to reference Swede H, Hajduk AM, Sharma J, et al. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer. 2014;134:1862–70.CrossRefPubMed Swede H, Hajduk AM, Sharma J, et al. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. Int J Cancer. 2014;134:1862–70.CrossRefPubMed
30.
go back to reference Sun ZQ, Han XN, Wang HJ, et al. Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol. 2014;20:8583–91.CrossRefPubMedPubMedCentral Sun ZQ, Han XN, Wang HJ, et al. Prognostic significance of preoperative fibrinogen in patients with colon cancer. World J Gastroenterol. 2014;20:8583–91.CrossRefPubMedPubMedCentral
31.
go back to reference Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11:325–51.CrossRefPubMed Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev. 1992;11:325–51.CrossRefPubMed
32.
go back to reference Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–9.PubMed Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–9.PubMed
33.
go back to reference Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.CrossRefPubMed Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22:2222–7.CrossRefPubMed
34.
go back to reference Ghezzi F, Cromi A, Siesto G, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol. 2010;119:309–13.CrossRefPubMed Ghezzi F, Cromi A, Siesto G, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer. Gynecol Oncol. 2010;119:309–13.CrossRefPubMed
35.
go back to reference Son HJ, Park JW, Chang HJ, et al. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol. 2013;20:2908–13.CrossRefPubMed Son HJ, Park JW, Chang HJ, et al. Preoperative plasma hyperfibrinogenemia is predictive of poor prognosis in patients with nonmetastatic colon cancer. Ann Surg Oncol. 2013;20:2908–13.CrossRefPubMed
36.
go back to reference Zhu JF, Cai L, Zhang XW, et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer. 2014;33:96–104.CrossRefPubMedPubMedCentral Zhu JF, Cai L, Zhang XW, et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer. 2014;33:96–104.CrossRefPubMedPubMedCentral
37.
go back to reference Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–95.CrossRefPubMedPubMedCentral Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer. 2002;86:389–95.CrossRefPubMedPubMedCentral
38.
go back to reference Cash JL, Norling LV, Perretti M. Resolution of inflammation: targeting GPCRs that interact with lipids and peptides. Drug Discov Today. 2014;19:1186–92.CrossRefPubMedPubMedCentral Cash JL, Norling LV, Perretti M. Resolution of inflammation: targeting GPCRs that interact with lipids and peptides. Drug Discov Today. 2014;19:1186–92.CrossRefPubMedPubMedCentral
39.
go back to reference Kumar JD, Holmberg C, Kandola S, et al. Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells. PLoS One. 2014;9, e104877.CrossRefPubMedPubMedCentral Kumar JD, Holmberg C, Kandola S, et al. Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells. PLoS One. 2014;9, e104877.CrossRefPubMedPubMedCentral
40.
go back to reference Wittamer V, Bondue B, Guillabert A, et al. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175:487–93.CrossRefPubMed Wittamer V, Bondue B, Guillabert A, et al. Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol. 2005;175:487–93.CrossRefPubMed
41.
go back to reference Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol. 2005;174:244–51.CrossRefPubMed Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol. 2005;174:244–51.CrossRefPubMed
43.
go back to reference Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008;205:2207–20.CrossRefPubMedPubMedCentral Zabel BA, Nakae S, Zuniga L, et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008;205:2207–20.CrossRefPubMedPubMedCentral
44.
go back to reference Barnea G, Strapps W, Herrada G, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A. 2008;105:64–9.CrossRefPubMed Barnea G, Strapps W, Herrada G, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci U S A. 2008;105:64–9.CrossRefPubMed
45.
go back to reference Zhang J, Jin HC, Zhu AK, et al. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides. 2014;61:7–11.CrossRefPubMed Zhang J, Jin HC, Zhu AK, et al. Prognostic significance of plasma chemerin levels in patients with gastric cancer. Peptides. 2014;61:7–11.CrossRefPubMed
46.
go back to reference Wang N, Wang QJ, Feng YY, et al. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2014;18:997–1004.CrossRefPubMed Wang N, Wang QJ, Feng YY, et al. Overexpression of chemerin was associated with tumor angiogenesis and poor clinical outcome in squamous cell carcinoma of the oral tongue. Clin Oral Investig. 2014;18:997–1004.CrossRefPubMed
48.
go back to reference Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24:275–81.CrossRefPubMed Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis. 2009;24:275–81.CrossRefPubMed
49.
go back to reference Lukanova A, Soderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:401–2.CrossRefPubMed Lukanova A, Soderberg S, Kaaks R, et al. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:401–2.CrossRefPubMed
50.
go back to reference Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol. 2014;20:7941–9.CrossRefPubMedPubMedCentral Joshi RK, Kim WJ, Lee SA. Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol. 2014;20:7941–9.CrossRefPubMedPubMedCentral
51.
go back to reference Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5:534–49.CrossRefPubMedPubMedCentral Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5:534–49.CrossRefPubMedPubMedCentral
52.
go back to reference Fazeli MS, Dashti H, Akbarzadeh S, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62:81–5.CrossRefPubMed Fazeli MS, Dashti H, Akbarzadeh S, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine. 2013;62:81–5.CrossRefPubMed
Metadata
Title
Inflammation and chemerin in colorectal cancer
Authors
Serpil Erdogan
Fatma Meric Yilmaz
Ozan Yazici
Ahmet Yozgat
Sevilay Sezer
Nuriye Ozdemir
Sema Uysal
Tugrul Purnak
Mehmet Ali Sendur
Ersan Ozaslan
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4483-y

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine